Apyx Medical Posts Record Revenue on AYON Demand, Narrows Losses
Event summary
- Record Q4 2025 revenue of $19.2M, up 34.7% YoY, driven by AYON Body Contouring System launch.
- Surgical Aesthetics revenue surged 38.1% YoY, with U.S. sales up nearly 50%.
- Net loss narrowed to $1.3M in Q4 2025 from $4.6M in Q4 2024.
- FY2026 revenue guidance set at $57.5M–$58.5M, up from $52.8M in FY2025.
- FDA 510(k) clearance for AYON label expansion expected mid-2026.
The big picture
Apyx Medical's strong Q4 2025 results reflect the market's appetite for its AYON system, which integrates multiple aesthetic procedures into one platform. The company's ability to scale this commercial opportunity will be critical as it competes in the rapidly evolving surgical aesthetics space, where demand for minimally invasive body contouring solutions is rising. The strategic pivot toward Surgical Aesthetics—now 83% of total revenue—highlights a broader industry trend toward specialized, high-margin medical devices.
What we're watching
- Commercial Scaling
- How Apyx Medical will sustain AYON's early demand momentum post-launch.
- Regulatory Timing
- Whether the mid-2026 FDA clearance for AYON's power liposuction expansion will meet expectations.
- Segment Shift
- The pace at which OEM revenue declines as Surgical Aesthetics becomes the primary growth driver.
Related topics